Tenofovir Rectal Douche to Prevent HIV Transmission
Status:
Completed
Trial end date:
2021-04-27
Target enrollment:
Participant gender:
Summary
DREAM-03 is an early phase-1, open label study to compare the safety, pharmacokinetics (PK),
pharmacodynamics (PD), and acceptability of 3 sequences of tenofovir (TFV) and non-medicated
douches. The overall goal is to inform the design of an extended safety study of an on-demand
and behaviorally congruent TFV douche to confer protection from HIV acquisition in an
outpatient pre-RAI context.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) University of Pittsburgh